Atrium Therapeutics, Inc. Common Stock (RNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $162.00M
Last updated: Nov 17, 2026 at 4:20 PM ET
Atrium Therapeutics, Inc. Common Stock (RNA) Statistics
Atrium Therapeutics, Inc. Common Stock (RNA) has a market cap of $162.00M and an enterprise value of $118.12M. Its share count is down 87.64% from a year earlier. It kept -229.67% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 27.09% below the market cap, as cash exceeds debt.
| Market Cap | $162.00M |
|---|---|
| Enterprise Value | $118.12M |
| Latest price (Nov 17, 2026) | $6.48 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.8x and 0.5x. Its year-end P/S ranged from 69.1x to 395.2x from 2020 to 2025.
| P/S Ratio | 2.8x |
|---|---|
| Forward P/S | 3.9x |
| P/B Ratio | 0.5x |
Price Statistics
The stock is down 90.85% over 52 weeks and trades 22.86% below its 50-day average.
| Beta (1Y) | 1.38 |
|---|---|
| 52-Week Change | -90.85% |
| 1-Month Change | -14.85% |
| 3-Month Change | -52.74% |
| 6-Month Change | -49.96% |
| 5-Year Change | -63.24% |
| Total Return (1Y) | -90.85% |
| Total Return (3Y CAGR) | +0.57% |
| Total Return (5Y CAGR) | -25.74% |
| Return vs SPY (1Y) | -102.41% |
| Max Drawdown (1Y) | -91.18% |
| Max Drawdown (3Y) | -91.18% |
| Sharpe Ratio (1Y) | -1.44 |
| Correlation with SPY (1Y) | 0.11 |
| 50-Day Average | $8.40 |
| 200-Day Average | $16.99 |
| 52-Week Range | $6.36 to $16.77 |
| RSI (14 Days) | 23.6 |
| Average Volume (20 Days) | 232.48K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.46x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 10.46x |
|---|---|
| Quick Ratio | 10.46x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -44.51% over the last 12 months, against a 5-year average of -32.91%.
| Return on Equity (ROE) | -43.49% |
|---|---|
| Return on Assets (ROA) | -33.77% |
| Return on Invested Capital (ROIC) | -44.51% |
| ROE (5Y Average) | -32.40% |
| ROA (5Y Average) | -27.17% |
| ROIC (5Y Average) | -32.91% |
| Asset Turnover | 0.14x |
| Receivables Turnover | 5.18x |
Scores
RNA has an Altman Z-Score of 1.12, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.12 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $38.82M over the last 12 months is up 86.02% from the 12 months before.
| Revenue | $38.82M |
|---|---|
| Revenue Growth (YoY) | +86.02% |
| Gross Profit | $16.38M |
| Operating Income | -$94.56M |
| Pretax Income | -$89.12M |
| Net Income | -$89.15M |
| Reported EPS (TTM) | -$3.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 77.66% of the $263.99M in total assets.
| Cash and Equivalents | $44.56M |
|---|---|
| Total Debt | $679.00K |
| Net Cash | $43.89M |
| Net Cash Per Share | $2.58 |
| Working Capital | $233.39M |
| Shareholder Equity | $205.02M |
| Book Value Per Share | $12.03 |
| Total Assets | $263.99M |
| Total Liabilities | $58.97M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.43M of capital spending, operating cash flow left -$83.12M of free cash flow.
| Operating Cash Flow | -$79.69M |
|---|---|
| Capital Expenditures | $3.43M |
| Free Cash Flow | -$83.12M |
| FCF Per Share | -$3.85 |
| Depreciation and Amortization | $968.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -243.60%.
| Gross Margin | 42.18% |
|---|---|
| Operating Margin | -243.60% |
| Pretax Margin | -229.58% |
| Net Margin | -229.67% |
| FCF Margin | -214.11% |
| Gross Margin (5Y Average) | 95.60% |
Growth
Revenue grew 26.38% a year over 3 years.
| Revenue Growth (3Y CAGR) | +26.38% |
|---|---|
| Revenue Growth (5Y CAGR) | +22.36% |
| Book Value Per Share Growth (2Y CAGR) | +35.63% |
| Tangible Book Per Share Growth (2Y CAGR) | +35.63% |
Dividends and Yields
RNA does not pay a dividend. Its free cash flow yield is -75.29%.
| FCF Yield | -75.29% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 7 similar companies, RNA has the 7th highest P/S.
P/S RatioPeer median 11.8x
ROICPeer median 116.36%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +21.28%
| P/S Ratio | 2.8x vs 11.8x median |
|---|---|
| ROIC | -44.51% vs 116.36% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +86.02% vs +21.28% median |
Analyst Forecast
Consensus estimates put revenue growth at -53.65% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -53.65% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RNA
What is RNA's market cap?
Atrium Therapeutics, Inc. Common Stock has a market cap of $162.00M. Its enterprise value, which adds debt and subtracts cash, is $118.12M.
How many shares of RNA are outstanding?
Atrium Therapeutics, Inc. Common Stock has 17.04M shares outstanding. The count is down 87.64% from a year earlier.
Does RNA pay a dividend?
No. Atrium Therapeutics, Inc. Common Stock does not pay a dividend.
How much debt does RNA have?
Atrium Therapeutics, Inc. Common Stock has $679.00K of total debt and $44.56M of cash and equivalents, a net cash position of $43.89M.
RNA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors